TB-500 Legal Status, FDA 503A Category, and Compounding Access

Active review, a 2026 advisory meeting, and momentum

TB-500 legal status is, right now, in motion — and the most concrete reason is on the FDA's own calendar. "TB-500 (free base)" and "TB-500 acetate" are individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[16]. The same agenda also lists BPC-157, KPV, and MOTs-C. Access to legally compounded TB-500 is under active FDA review and may expand in 2026.

Read that sentence precisely, because the precision is the point. A PCAC agenda listing is a scheduled evaluation and discussion — not a listing decision, not a reclassification, and not a change in current status ^[16]. A PCAC discussion is advisory; inclusion on a final 503A bulks list is decided by FDA rulemaking informed by that committee ^[18]. The meeting confirms TB-500 is being evaluated rather than ignored. It does not tell us the outcome, and no outcome should be assumed or dated.

The current FDA fact

Here is the present-tense status, stated the way the FDA states it. The substance FDA lists as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" is a research peptide that FDA placed in 503A "Category 2" — bulk substances that may present significant safety risks — effective with FDA's September 29, 2023 update to the list of nominated substances, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information ^[17]. FDA's own list entry establishes the relationship: TB-500 is the LKKTETQ fragment associated with thymosin beta-4.

Two consequences follow. First, as a Category 2 substance, TB-500 is not within FDA's enforcement-discretion policy for 503A compounding ^[18]. Second, TB-500 is not an FDA-approved drug — FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and TB-500 is neither ^[18].

What about reports of a 2026 reclassification? Some commercial and clinic sources have described an early-2026 expectation that many Category 2 peptides would move back toward Category 1, and some assert specific dates on which substances were "removed" from Category 2 ^[18]. None of those claims could be confirmed from an authoritative FDA source, and this page does not treat any reclassification as having occurred. The fact that TB-500 remains on the July 2026 PCAC agenda is consistent with its evaluation being ongoing rather than resolved ^[16].

How 503A and 503B compounding are structured

Under the U.S. Federal Food, Drug, and Cosmetic Act, compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA inspection ^[18].

The ingredient rule is the hinge. A compounder may use a bulk drug substance only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet listed are evaluated by FDA through a public nomination process with input from the PCAC ^[18]. Under FDA's interim policy, Category 2 substances were identified as raising significant safety risks and are not covered by the enforcement-discretion policy that applies to Category 1 ^[18]. On January 7, 2025, FDA finalized a revised policy under which it no longer sorts newly nominated substances into these numbered categories — but substances already in Category 2 are not afforded that discretion even if nominations are updated ^[18].

How legally compounded peptide access works

In general terms, a legally compounded medication is prepared only after an individual patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription ^[18]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility ^[18].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued ^[18]. It is a route to a licensed-prescriber consultation, not a separate legal status: telehealth does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[18]. And the ingredient-eligibility caveat governs the whole pathway — a compounder may use an active ingredient only if it is eligible under the 503A/503B bulk-substance rules, and a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[18]. For TB-500, that caveat is the operative one today.

This page describes the regulatory landscape in general terms. It does not name any pharmacy, clinic, telehealth provider, or vendor; it does not provide dosing or administration instructions; and it is not an offer to sell or supply any substance. It is general information about the regulatory landscape, not medical or legal advice.

Access and regulatory questions

Is TB-500 legal?

TB-500 is not an FDA-approved drug, and FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 as a bulk substance that may present significant safety risks ^[17]. As a Category 2 substance it is not within FDA's enforcement-discretion policy for 503A compounding ^[18]. This is general information about its U.S. regulatory standing, not legal advice.

Can you get TB-500 from a compounding pharmacy?

Legally compounded medications require a licensed-prescriber evaluation and a valid, patient-specific prescription, dispensed by a 503A pharmacy or sourced from a 503B outsourcing facility ^[18]. A compounder may use an ingredient only if it is eligible under the bulk-substance rules; a Category 2 substance like TB-500 is not eligible for routine 503A compounding while that status stands ^[17].

What is the FDA 503A status of TB-500?

FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 — bulk substances that may present significant safety risks — effective with its September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information ^[17]. TB-500 is also listed on the July 23–24, 2026 PCAC agenda for evaluation ^[16], which is a scheduled discussion, not a decision.

Is TB-500 banned by WADA and in competitive sports?

Yes. TB-500 and thymosin beta-4 fall under WADA prohibited peptide, growth-factor, and tissue-repair categories, banned both in and out of competition for the relevant classes ^[13]. It is detected by LC-MS anti-doping assays in equine and human matrices.

Is TB-500 FDA approved?

No. TB-500 has no approved therapeutic indication; it is a research chemical and veterinary-context substance, not an approved medicine ^[17]. FDA approval of a finished drug is a separate question from compounding eligibility, and TB-500 meets neither.